ALSO NOTED: Rituxan data impresses; MediGene launches Phase I; Biogen stock hit on generic prospects; and much more...

> Preliminary data from a Phase IIb study of Rituxan shows that it improved the symptoms of patients who had failed to respond to other rheumatoid arthritis drugs. Release

> Germany's MediGene has begun a Phase I trial of an experimental drug targeted at brain tumors. The trial of G207 will involve 20 patients. Story

> The prospect of a generic Avonex hitting the market for MS has driven down shares of Biogen Idec. Article

> India's Ranbaxy has acquired a portfolio of generic drugs from a Spanish company. Story

> Japan's Chugai has announced a supply plan for anti-influenza drugs. Release

> Germany's Schering has sold its 25 percent stake in Medac to Medac shareholders. Story

And Finally... Two top US health officials have told an Indian minister that they will help the country's drug industry upgrade to US standards so they can more easily sell their products in North America. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.